VBI Vaccines在IDWeek 2019TM上宣布突破口头报告

StephenW

VBI Vaccines Announces Late-Breaker Oral Presentation at IDWeek 2019™
CAMBRIDGE, Mass.--(BUSINESS WIRE)--

VBI Vaccines Inc. (VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the company’s abstract titled, “Trivalent hepatitis B (HepB) vaccine yields superior seroprotection rates in adults: results from the phase 3 double-blind, randomized study comparing immunogenicity and safety of a 3-Dose regimen of Sci-B-Vac™ and Engerix B® (PROTECT),” has been selected for a late-breaker oral presentation at IDWeek 2019™, in Washington, D.C., on Friday, October 4, 2019.

Dr. Joanne Langley, M.D., Professor of Pediatrics and Community Health and Epidemiology, CIHR-GSK Chair in Pediatric Vaccinology, Dalhousie University, and Head of the Division of Infectious Disease, IWK Health Centre, and principal investigator of the PROTECT study, will deliver the oral presentation. Dr. Langley will discuss the top-line data from the PROTECT study, a pivotal Phase 3 study designed to evaluate the efficacy and safety of a 10µg dose of Sci-B-Vac®, VBI’s trivalent hepatitis B vaccine, compared with a 20µg dose of the comparator vaccine, Engerix-B®. Notably, Dr. Langley will highlight the two successfully-met co-primary endpoints and detailed seroprotection data in key patient subgroups, including by age group, gender, diabetic status, body mass index, and smoking status.

Presentation Details

- Abstract #: 717615
- Session: 184 - Late Breaker Oral Abstract Session 2
- Location: Walter E. Washington Convention Center, Room 209 ABC
- Date: Friday, October 4, 2019
- Time: 2:35 – 2:45 PM ET
- Event Website: https://idweek.org

About VBI Vaccines Inc.

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only commercially-approved trivalent hepatitis B vaccine, Sci-B-Vac®, which is approved for use in Israel and 10 other countries and is currently in a Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s eVLP Platform technology allows for the development of enveloped virus-like particle (eVLP) vaccines that closely mimic the target virus to elicit a potent immune response. Integrating its cytomegalovirus (CMV) expertise with the eVLP platform technology, VBI’s lead eVLP program candidates include a prophylactic CMV vaccine candidate and a glioblastoma (GBM) vaccine immunotherapeutic candidate. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

Website Home: http://www.vbivaccines.com/

StephenW

VBI Vaccines在IDWeek 2019TM上宣布突破口头报告
马萨诸塞州剑桥市-（美国商业资讯）-

商业级生物制药公司VBI Vaccines Inc.（VBIV）（“ VBI”）今天宣布，该公司的标题为“三价乙型肝炎（HepB）疫苗”的摘要具有出色的血清保护作用成人发病率：来自3期双盲，随机研究的结果，该研究比较了Sci-B-VacTM和EngerixB®（PROTECT）3剂治疗方案的免疫原性和安全性，”于2019年10月4日星期五在华盛顿特区的IDWeek 2019TM上举行。

达尔豪斯大学CIHR-GSK儿科疫苗学教授，IWK卫生中心传染病科主任，PROTECT研究的首席研究员Joanne Langley博士，医学博士，CIHR-GSK儿科和社区卫生与流行病学教授口头陈述。 Langley博士将讨论PROTECT研究的主要数据，该研究是一项关键的3期研究，旨在评估10μg剂量的Sci-B-Vac®（VBI的三价乙型肝炎疫苗）和20μg剂量的Sci-B-Vac®的疗效和安全性。比较疫苗Engerix-B®。值得注意的是，Langley博士将重点介绍两个成功达到的主要共同终点以及关键患者亚组的详细血清保护数据，包括按年龄组，性别，糖尿病状态，体重指数和吸烟状态。

演讲内容

-摘要＃：717615
-场次：184-Late Breaker Oral Abstract Session 2
-地点：沃尔特·E·华盛顿会议中心，ABC 209室
-日期：2019年10月4日星期五
-时间：美国东部时间下午2:35 – 2:45
-活动网站：https：//idweek.org

关于VBI疫苗公司

VBI疫苗公司（Nasdaq：VBIV）是一家商业生物制药公司，致力于开发下一代疫苗，以满足传染病和免疫肿瘤学的未满足需求。 VBI正在使用唯一经商业批准的三价乙型肝炎疫苗Sci-B-Vac®来促进乙型肝炎的预防和治疗，该疫苗已获批准在以色列和其他10个国家使用，目前正处于第三阶段计划中。美国，欧洲和加拿大，并且正在开发针对慢性乙型肝炎的功能性治疗的免疫疗法。VBI的eVLP平台技术可开发包膜病毒样颗粒（eVLP）疫苗，该疫苗紧密模拟目标病毒以产生有效的免疫反应。 VBI的主要eVLP计划候选人将其巨细胞病毒（CMV）专业知识与eVLP平台技术相结合，包括预防性CMV疫苗候选人和成胶质细胞瘤（GBM）疫苗免疫治疗候选人。 VBI的总部位于马萨诸塞州剑桥市，在加拿大渥太华设有研究机构，并在以色列雷霍沃特设有研究和制造机构。

网站主页：http://www.vbivaccines.com/

乙肝人1949

这个和目前使用的疫苗有何异同?有治疗作用吗。抑或是仅仅能预防而已。那样就没有大意义了